ClinicalTrials.gg

Hearing Loss clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 796 studies for Hearing Loss across more than 10 countries. 194 are recruiting or about to start. 539 of them are mainly about Hearing Loss (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 10 narrower conditions too, such as Hearing Loss, Sensorineural: 1,386 studies, 357 open.

ClinicalTrials.gov finds 1,540 studies for Hearing Loss. How that becomes 796 here

This page counts the studies the registry files under Hearing Loss, and those it files under no condition that list Hearing Lossthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,540Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −588Filed under a narrower condition, counted on its own pageHearing Loss, Sensorineural 258 · Deafness 79 · Hearing Loss, Conductive 54 · Hearing Loss, Sudden 46 · Usher Syndromes 30 · Presbycusis 30 · 4 more
  3. −28List Hearing Loss as a condition, but the registry did not file them under itMost often written as “Hearing Loss, High-Frequency” (3), “Hearing Loss, Functional” (3), and “Age-related Hearing Impairment 1” (2). The registry filed them under other conditions only, most often Hearing Loss, High-Frequency (5) and Communication (3).
  4. −128Match it another way38 name it in the title, 6 in a keyword, and 84 by a synonym or other text the search reads.
  5. 796The count on this page27 of them list Hearing Loss in their own words; the registry filed them under no condition.

Status

Completed
426
Recruiting
124
Status unknown
75
Not yet recruiting
47
Terminated
37
Withdrawn
36

Phase

Phase 2
56
Phase 1
33
Phase 3
14
Phase 4
10
Early Phase 1
8

Where

United States
321
France
59
Switzerland
52
United Kingdom
45
Australia
45
Canada
42

Who develops what

Add Hearing Loss to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 5 companies, 3 with this as their studies’ main aim; 2 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Truway Health and Lunan Pharmaceutical Group here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
PrednisoloneRecent, limitedPhase 4 trial recorded
Evidence
  • NCT05776459 · AudioCure Pharma GmbH · Phase 2 · comparator · “Prednisolone” · registered Mar 2023
Sanofi15% of its industry studies11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
ebselen☆ Track1 live phase-3 study: NCT06859788Sound Pharmaceuticals, Incorporated
IsosorbidePhase 4 trial recorded☆ Track1 live phase-3 study: NCT06765993Lunan Pharmaceutical Group

The 2 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.ebselen · Sound Pharmaceuticals, Incorporated · Phase 3 registry mapping onlyNCT06859788 SPI-1005 for the Treatment of Meniere's Disease (Open Label) — primary endpoint: Incidence of Treatment-Emergent Adverse Events · 200 enrolled
  • Dec 2026 est.ebselen · Sound Pharmaceuticals, Incorporated · Phase 2 main aimNCT06340633 SPI-1005 in Adults Receiving Cochlear Implant — primary endpoint: Number of Participants with Treatment Emergent Adverse Events (TEAE) · 40 enrolled
  • 30 Jun 2027 est.Isosorbide · Lunan Pharmaceutical Group · Phase 3 main aimNCT06765993 Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease — primary endpoint: The changes from baseline in the number of vertigo attacks due to Meniere's disease during the treatment period · 234 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hearing Loss studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Corticosteroids 2 open

Coming up

68studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 124 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 42 (34%) stop at 75 or younger. 46 (37%) take children under 18. 0 (0%) are for women only and 2 (2%) for men only; 46 (37%) take healthy volunteers.

Recruiting studies that take each age, of 124
AgeWomenMen
1033 (27%)33 (27%)
1884 (68%)86 (69%)
3082 (66%)84 (68%)
4083 (67%)85 (69%)
5086 (69%)87 (70%)
6591 (73%)92 (74%)
7586 (69%)87 (70%)
8575 (60%)76 (61%)

Across all 796 studies, recruiting or not: 29% stop at 75 or younger and 23% at 65; 29% take children; 1% are for women only and 1% for men only; 33% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hearing Loss studies take

Of 323 interventional studies with no phase under Hearing Loss, half reached primary completion within 19 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase19 mo5–42 · 323 studies5 mo2–15 · 126 studies32 mo14–59 · 197 studies
Observational42 mo15–83 · 99 studies—50 mo14–179 · 77 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 796. Browse all 796 → or search them.